Richmond, BC, January 7, 2020--Neovasc, Inc. (NASDAQ, TSX: NVCN): NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that it has been selected as a finalist in this year's Fierce Innovation Awards - LifeSciences Edition, a peer reviewed awards program from the publisher of FierceBiotech and FiercePharma.
|